- Home
- THAR vs NCNA Comparison
THAR vs NCNA Comparison
Compare THAR & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THAR
- NCNA
- Stock Information
- Founded
- THAR 2017
- NCNA 1997
- Country
- THAR United States
- NCNA United Kingdom
- Employees
- THAR N/A
- NCNA N/A
- Industry
- THAR Biotechnology: Pharmaceutical Preparations
- NCNA Biotechnology: Pharmaceutical Preparations
- Sector
- THAR Health Care
- NCNA Health Care
- Exchange
- THAR Nasdaq
- NCNA Nasdaq
- Market Cap
- THAR 4.0M
- NCNA 3.4M
- IPO Year
- THAR 2022
- NCNA 2017
- Fundamental
- Price
- THAR $1.25
- NCNA $0.88
- Analyst Decision
- THAR Strong Buy
- NCNA Buy
- Analyst Count
- THAR 1
- NCNA 2
- Target Price
- THAR $17.00
- NCNA $25.00
- AVG Volume (30 Days)
- THAR 135.2K
- NCNA 118.8K
- Earning Date
- THAR 05-08-2025
- NCNA 05-15-2025
- Dividend Yield
- THAR N/A
- NCNA N/A
- EPS Growth
- THAR N/A
- NCNA N/A
- EPS
- THAR N/A
- NCNA N/A
- Revenue
- THAR N/A
- NCNA N/A
- Revenue This Year
- THAR N/A
- NCNA N/A
- Revenue Next Year
- THAR N/A
- NCNA N/A
- P/E Ratio
- THAR N/A
- NCNA N/A
- Revenue Growth
- THAR N/A
- NCNA N/A
- 52 Week Low
- THAR $1.20
- NCNA $0.69
- 52 Week High
- THAR $7.13
- NCNA $10.79
- Technical
- Relative Strength Index (RSI)
- THAR 32.14
- NCNA 49.33
- Support Level
- THAR $1.20
- NCNA $0.81
- Resistance Level
- THAR $1.47
- NCNA $0.98
- Average True Range (ATR)
- THAR 0.15
- NCNA 0.14
- MACD
- THAR -0.01
- NCNA 0.01
- Stochastic Oscillator
- THAR 2.04
- NCNA 32.19
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.